Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...
InvestorsHub on MSN
Compass Pathways gains after FDA clears IND for PTSD trial of COMP360
Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...
Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025. CTX-10726 (a novel PD-1 x ...
The FDA has accepted an investigational new drug application from a global biotechnology company for its investigational, ...
On Monday, William Blair initiated coverage of Compass Therapeutics, Inc. (NASDAQ: CMPX), citing the potential success of its lead program, tovecimig, a DLL4xVEGF bispecific antibody, in previously ...
BOSTON - Compass Therapeutics, Inc. (NASDAQ:CMPX) announced Tuesday that key survival analyses for its lead drug tovecimig in biliary tract cancer remain on track for late Q1 2026, according to a ...
Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results